Multiple Sclerosis is entering its 2024 ERA – that means new treatments on the horizon and a new changes to the McDonald DIAGNOSTIC CRITERIA!
Some of these changes are quite significant – to get everyone up to speed I made this thread!
Grateful to be recognized by my department and SO VERY proud of our amazing Multiple Sclerosis/Neuroimmunology division at Beth Israel Deaconess Medical Center 🧠👏🥰🧡
One of the things I love most about being an MS specialist is thinking carefully and critically about diagnosis. I'm excited to share my N2 publication on a very rare and unique case of a patient with MS who later went on to develop a cancer called diffuse midline glioma (new tx)
What an honor to meet and hear from Dr Mitch Rabkin, previous CEO of Beth Israel. His powerful heart-felt stories left me at times with tears of emotion. The future of BIDMC is bright!! @SmithBIDMC@harvardmed@HMFPBoston
https://t.co/qaUxCcXnTz
Data from a survey of 17,000 people with MS sends a loud & clear message -- we need better tools and clinical empathy for the invisible symptoms of MS. We're talking about it. On RealTalk MS #MultipleSclerosis
Fatigue is a huge issue that affects our patients with multiple sclerosis 🧠Proud of this work led by Dr. Jacob Sloane and members of our amazing Multiple Sclerosis/Neuroimmunology Center at Beth Israel Deaconess Medical Center. @mssociety@HMFPBoston
https://t.co/RO4apGz2bN
Excited to announce my latest publication in Radiology, which is a state-of-the-art review of advanced MRI biomarkers in the updated 2024 McDonald Criteria used in diagnosing Multiple Sclerosis 🧠.
https://t.co/jW5O8IJyDd
This was an amazing collaboration with colleagues at the Massachusetts General Hospital and The Martinos Center for Biomedical Imaging. And it has been wonderful to lead this publication, while starting my new position as an attending and MS fellowship program director